Proteomics

Dataset Information

0

Small Molecule Degraders of the Hepatitis C Virus Protease Reduce Susceptibility to Resistance Mutations

ABSTRACT: Targeted protein degradation (TPD) has emerged as a promising new drug development paradigm. We leveraged this strategy to develop a new class of small molecule antivirals that induce proteasomal degradation of viral proteins. Telaprevir, a ‘reversible-covalent’ inhibitor that binds to the hepatitis C virus (HCV) protease active site was conjugated to ligands that recruit the CRL4CRBN ligase complex, yielding compounds that can both inhibit and induce the degradation of the HCV NS3/4A protease. We developed an optimized degrader, DGY-08-097, that potently inhibits HCV in a cellular infection model and demonstrate that protein degradation contributes to its antiviral activity. Finally, we show that this new class of antiviral agents can overcome viral variants that confer resistance to traditional enzymatic inhibitors such as telaprevir. Overall, our work provides proof-of-concept that targeted protein degradation may provide a new paradigm for the development of antivirals with superior resistance profiles.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Eric Fischer  

LAB HEAD: Eric Fischer

PROVIDER: PXD014346 | Pride | 2019-07-03

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
esf_1628.raw Raw
esf_1629.raw Raw
esf_1630.raw Raw
esf_1631.raw Raw
esf_1632.raw Raw
Items per page:
1 - 5 of 25
altmetric image

Publications

Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations.

de Wispelaere Mélissanne M   Du Guangyan G   Donovan Katherine A KA   Zhang Tinghu T   Eleuteri Nicholas A NA   Yuan Jingting C JC   Kalabathula Joann J   Nowak Radosław P RP   Fischer Eric S ES   Gray Nathanael S NS   Yang Priscilla L PL  

Nature communications 20190801 1

Targeted protein degradation is a promising drug development paradigm. Here we leverage this strategy to develop a new class of small molecule antivirals that induce proteasomal degradation of viral proteins. Telaprevir, a reversible-covalent inhibitor that binds to the hepatitis C virus (HCV) protease active site is conjugated to ligands that recruit the CRL4<sup>CRBN</sup> ligase complex, yielding compounds that can both inhibit and induce the degradation of the HCV NS3/4A protease. An optimiz  ...[more]

Similar Datasets

Proteomics Antiviral HCV Treatment Induces Rapid Proteomic and Phospho-proteomic Changes in Hepatic Interferon and ERK1/2 Signaling Pathways
2023-03-11 | PXD024846 | Pride
Proteomics Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics
2023-06-15 | PXD042352 | Pride
Transcriptomics Virus genotype-dependent gene expression in progressive liver disease prior to the development of advanced cirrhosis
2019-06-01 | E-MTAB-7751 | biostudies-arrayexpress
Proteomics Discovery of a Small Molecule Degrader that Sustains pan-AKT Degradation and Downstream Signaling Effects
2019-11-27 | PXD015207 | Pride
Transcriptomics Expression data of genome-length HCV RNA-replicating OL8(3.5Y) cells and OL8(3.5Y)-derived ribavirin-resistant cells
2014-08-30 | E-GEOD-60948 | biostudies-arrayexpress
Proteomics Small molecule-induced polymerization triggers degradation of BCL6
2020-11-20 | PXD016185 | Pride
Transcriptomics Expression data of genome-length HCV RNA-replicating OL8(3.5Y) cells and OL8(3.5Y)-derived ribavirin-resistant cells
2014-08-30 | GSE60948 | GEO
Proteomics Reprogramming the E3 ubiquitin ligase CRL4CRBN to degrade Helios
2021-05-26 | PXD016168 | Pride
Proteomics Bruton’s Tyrosine Kinase Degradation as a Therapeutic Strategy for Cancer
2019-01-25 | PXD010568 | Pride
Proteomics Unmasking functional redundancy of deubiquitylases enables specificity profiling and discovery of novel proteasome substrates
2022-09-02 | PXD016164 | Pride